keyword
MENU ▼
Read by QxMD icon Read
search

Neuro-oncology

keyword
https://www.readbyqxmd.com/read/29754968/recurrent-pseudoprogression-in-isocitrate-dehydrogenase-1-mutant-glioblastoma
#1
Sied Kebir, Laurèl Rauschenbach, Gerrit H Gielen, Niklas Schäfer, Theophilos Tzaridis, Björn Scheffler, Frank A Giordano, Lazaros Lazaridis, Ulrich Herrlinger, Martin Glas
In a subset of glioblastoma (GBM) patients, the differentiation between tumor progression and tumor pseudoprogression (PsP) is challenging. This case describes a male patient suffering from isocitrate dehydrogenase 1 (IDH1) mutant GBM who demonstrated an increasing contrast-enhancing (CE) lesion on a cranial magnetic resonance imaging (cMRI) scan 8 months after radiochemotherapy. In accordance with the response assessment in neuro-oncology (RANO) criteria, the cMRI lesion was classified as recurrent tumor, although 18 F-fluoroethyl-L-tyrosine positron emission tomography (18 F-FET-PET) did not indicate vital tumor tissue...
May 10, 2018: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/29754199/treatment-and-survival-of-glioblastoma-patients-in-denmark-the-danish-neuro-oncology-registry-2009-2014
#2
Steinbjørn Hansen, Birthe Krogh Rasmussen, René Johannes Laursen, Michael Kosteljanetz, Henrik Schultz, Bente Mertz Nørgård, Rikke Guldberg, Kim Oren Gradel
BACKGROUND: As many glioblastoma patients are in a poor condition they are unable to undergo the full treatment documented in clinical trials. We aimed to examine the survival and its relationship to clinical characteristics and treatment in a nationwide population of glioblastoma patients in Denmark. METHODS: We included prospectively recorded clinical data from 1364 adult patients with histologically verified glioblastoma from the Danish Neuro-Oncology Registry, 2009-2014...
May 12, 2018: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29750396/a-phase-1-2-dose-finding-safety-and-activity-study-of-cabazitaxel-in-pediatric-patients-with-refractory-solid-tumors-including-tumors-of-the-central-nervous-system
#3
Peter E Manley, Tanya Trippett, Amy A Smith, Margaret E Macy, Sarah E S Leary, Jessica Boklan, Kenneth J Cohen, Stewart Goldman, Lindsay B Kilburn, Girish Dhall, Jeanne Devin, Cynthia E Herzog, Sonia Partap, Floris Fauchet, Emmy Badreddine, John P Bernard, Susan N Chi
BACKGROUND: This phase 1/2 study (NCT01751308) evaluated cabazitaxel in pediatric patients. Phase 1 determined the maximum tolerated dose (MTD) in patients with recurrent/refractory solid tumors, including central nervous system (CNS) tumors. Phase 2 evaluated activity in pediatric recurrent high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG). PROCEDURE: In phase 1, a 3 + 3 dose-escalation study design was followed. Cabazitaxel was administered at a starting dose of 20 mg/m2 ...
May 11, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29742885/malignant-brain-tumours-in-children-present-and-future-perspectives
#4
REVIEW
James T Rutka
In contrast to many of the malignant tumors that occur in the central nervous system in adults, the management, responses to therapy, and future perspectives of children with malignant lesions of the brain hold considerable promise. Within the past 5 years, remarkable progress has been made with our understanding of the basic biology of the molecular genetics of several pediatric malignant brain tumors including medulloblastoma, ependymoma, atypical teratoid rhabdoid tumour, and high grade glioma/diffuse intrinsic pontine glioma...
May 2018: Journal of Korean Neurosurgical Society
https://www.readbyqxmd.com/read/29727391/reflections-on-50-years-of-neuroscience-nursing-neuro-oncology-moving-forward-by-looking-back
#5
Marilyn E Reed, Patricia P Anthony, Priscilla B Rosenfeld, Brandi L Ligon, Estelle M Doris, Sherry W Fox
During the past 50 years, there have been more than 100 articles published in the Journal of Neuroscience Nursing covering the topic of neuro-oncology. This article will explore the historical implications and milestones from these articles. The analysis highlights the scope and depth of the many articles as they relate to the advancements in neuro-oncology.
June 2018: Journal of Neuroscience Nursing: Journal of the American Association of Neuroscience Nurses
https://www.readbyqxmd.com/read/29726782/laser-ablation-after-stereotactic-radiosurgery-a-multicenter-prospective-study-in-patients-with-metastatic-brain-tumors-and-radiation-necrosis
#6
Manmeet Ahluwalia, Gene H Barnett, Di Deng, Stephen B Tatter, Adrian W Laxton, Alireza M Mohammadi, Eric Leuthardt, Roukoz Chamoun, Kevin Judy, Anthony Asher, Marco Essig, Jorg Dietrich, Veronica L Chiang
OBJECTIVE Laser Ablation After Stereotactic Radiosurgery (LAASR) is a multicenter prospective study of laser interstitial thermal (LITT) ablation in patients with radiographic progression after stereotactic radiosurgery for brain metastases. METHODS Patients with a Karnofsky Performance Scale (KPS) score ≥ 60, an age > 18 years, and surgical eligibility were included in this study. The primary outcome was local progression-free survival (PFS) assessed using the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria...
May 4, 2018: Journal of Neurosurgery
https://www.readbyqxmd.com/read/29708785/interval-change-in-diffusion-and-perfusion-mri-parameters-for-the-assessment-of-pseudoprogression-in-cerebral-metastases-treated-with-stereotactic-radiation
#7
James R Knitter, William K Erly, Baldassarre D Stea, Gerald M Lemole, Isabelle M Germano, Amish H Doshi, Kambiz Nael
OBJECTIVE: Apparent increases in the size of cerebral metastases after stereotactic radiosurgery (SRS) can be caused by pseudoprogression or true disease progression, which poses a diagnostic challenge at conventional MRI. The purpose of this study was to assess whether interval change in DWI and perfusion MRI parameters can differentiate pseudoprogression from progressive disease after treatment with SRS. MATERIALS AND METHODS: Patients with apparent growth of cerebral metastases after SRS treatment who underwent pre- and post-SRS DWI, dynamic susceptibility contrast (DSC)-MRI, and perfusion dynamic contrast-enhanced (DCE)-MRI were retrospectively evaluated...
April 30, 2018: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/29704209/neurologic-manifestations-of-elderly-patients-with-cancer
#8
Bernardo Cacho-Díaz, Nydia A Lorenzana-Mendoza, Gervith Reyes-Soto, José A Ávila-Funes, Ana P Navarrete-Reyes
BACKGROUND: The incidence of cancer is an age-related phenomenon; therefore, the interest on clinical manifestations, diagnostic approach and treatment strategies for older patients diagnosed with cancer has increased lately. Neurologic symptoms are one of the main reasons for consultation and a common cause of decreased quality of life among cancer patients. AIMS: To identify the neurologic manifestations of patients ≥ 65 years of age diagnosed with cancer and compare them to those presented by a younger population...
April 27, 2018: Aging Clinical and Experimental Research
https://www.readbyqxmd.com/read/29696948/role-of-amino-acid-pet-in-hggs-limitations-and-perspectives
#9
Antoine Verger, Javier Arbizu, Ian Law
Positron emission tomography (PET) using radiolabelled amino acids was recently recommended by the Response Assessment in Neuro-Oncology (RANO) working group as an additional tool in the diagnostic assessment of brain tumours. The aim of this review is to summarise available literature data on the role of amino-acid PET imaging in high-grade gliomas (HGGs), with regard to diagnosis, treatment planning and follow-up of these tumours. Indeed, amino acid PET applications are multiple throughout the evolution of HGGs...
April 26, 2018: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29692920/brain-tumor-biobanking-in-the-precision-medicine-era-building-a-high-quality-resource-for-translational-research-in-neuro-oncology
#10
REVIEW
Quinn T Ostrom, Karen Devine, Jordonna Fulop, Yingli Wolinsky, Peter Liao, Lindsay Stetson, Marta Couce, Andrew E Sloan, Jill S Barnholtz-Sloan
The growth of precision medicine has made access to biobanks with high-quality, well-annotated neuro-oncology biospecimens critical. Developing and maintaining neuro-oncology biobanks is best accomplished through multidisciplinary collaboration between clinicians and researchers. Balancing the needs and leveraging the skills of all stakeholders in this multidisciplinary effort is of utmost importance. Collaboration with a multidisciplinary team of clinicians, health care team members, and institutions, as well as patients and their families, is essential for access to participants in order to obtain informed consent, collect samples under strict standard operating procedures, and accurate and relevant clinical annotation...
December 2017: Neuro-oncology Practice
https://www.readbyqxmd.com/read/29681812/a-58-year-old-woman-with-left-sided-weakness-and-a-history-of-a-pediatric-brain-tumor-a-case-report
#11
Shaakir Hasan, Michael J Gigliotti, Melvin Deutsch, Stacey L Reed, Rodney E Wegner
Background: An uncommon but well-established complication of cranial irradiation is secondary neoplasm. This case presentation documents a radiation-induced malignant glioma 55 years after being diagnosed with "cerebral sarcoma," now defined as atypical meningioma. This not only represents the longest reported latency period for a patient initially receiving over 30 Gy, but also provides a valuable historical perspective of neuro-oncology. Clinical Presentation: A 58-year-old female presenting with progressive left-sided upper and lower extremity weakness with a past medical history significant for "cerebral sarcoma" was diagnosed with glioblastoma multiforme...
January 2018: Case Reports in Oncology
https://www.readbyqxmd.com/read/29674411/sequential-apparent-diffusion-coefficient-for-assessment-of-tumor-progression-in-patients-with-low-grade-glioma
#12
I E Chen, N Swinburne, N M Tsankova, M M Hefti, A Aggarwal, A H Doshi, A Hormigo, B N Delman, K Nael
BACKGROUND AND PURPOSE: Early and accurate identification of tumor progression in patients with low-grade gliomas is challenging. We aimed to assess the role of quantitative ADC analysis in the sequential follow-up of patients with low-grade gliomas as a potential imaging marker of tumor stability or progression. MATERIALS AND METHODS: In this retrospective study, patients with a diagnosis of low-grade glioma with at least 12 months of imaging follow-up were retrospectively reviewed...
April 19, 2018: AJNR. American Journal of Neuroradiology
https://www.readbyqxmd.com/read/29666296/phase-ii-study-to-evaluate-the-efficacy-and-safety-of-rilotumumab-and-bevacizumab-in-subjects-with-recurrent-malignant-glioma
#13
Mary Lou Affronti, Jennifer Gamboa Jackman, Frances McSherry, James E Herndon, Elwood C Massey, Eric Lipp, Annick Desjardins, Henry S Friedman, Gordana Vlahovic, James Vredenburgh, Katherine B Peters
LESSONS LEARNED: Due to evolving imaging criteria in brain tumors and variation in magnetic resonance imaging evaluation, it is not ideal to use response rate as a primary objective. Future studies involving antiangiogenic agents should use overall survival.Disease-expected toxicities should be considered when defining the clinical significance of an adverse event. For example, vascular thromboembolic events are common in brain tumor patients and should not be attributed to the study drug in the safety analysis...
April 17, 2018: Oncologist
https://www.readbyqxmd.com/read/29662558/radiomics-as-a-quantitative-imaging-biomarker-practical-considerations-and-the-current-standpoint-in-neuro-oncologic-studies
#14
REVIEW
Ji Eun Park, Ho Sung Kim
Radiomics utilizes high-dimensional imaging data to discover the association with diagnostic, prognostic, predictive endpoint or radiogenomics. It is an emerging field of study that potentially depicts the intratumoral heterogeneity from quantitative and classified high-throughput data. The radiomics approach has an analytic pipeline where the imaging features are extracted, processed and analyzed. At this point, special data handling is essential because it faces issues of a high-dimensional biomarker compared to a single biomarker approach...
April 2018: Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29656021/next-generation-neuro-oncology
#15
REVIEW
Michael Weller
Neuro-oncology has evolved as a growing, but still small, highly specialised and multidisciplinary field at the interface of several diagnostic and therapeutic disciplines. The major challenge in the field of primary tumours is to translate the almost unique progress in deciphering the highly complex molecular genetic nature of many primary brain tumours, notably glioblastoma, into advances that allow for clinical benefit for affected patients. Furthermore, metastases to the central nervous system are an increasingly prevalent complication in many systemic cancers...
April 12, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29651966/specific-cytostatic-and-cytotoxic-effect-of-dihydrochelerythrine-in-glioblastoma-cells-role-of-nf-kb-b-catenin-and-stat3-il-6-pathways
#16
Tereza Cristina Costa Silva, Noelio de Jesus Menezes-Filho, Giselle Pinto de Faria Lopes, Diego Madureira de Oliveira, Ezequiel Pereira, Bruno Penas Seara Pitanga, Eudes S Velozo, Songeli Menezes Freire, Jorge Clarencio de Souza Andrade, Helena Lobo Borges, Stevens Kastrup Rehen, Vivaldo Moura-Neto, Silvia Lima Costa
A glioblastoma is a primary CNS tumor that is more aggressive and lethal than other brain tumors. Its location, rapid proliferation, invasive growth, angiogenesis and immunosuppression are the main factors that limit its treatment, making it a major challenge to neuro-oncology. OBJECTIVE: This study investigated the in vitro effects of the alkaloid dihydrochelerythrine (DHC), which is extracted from Zanthoxylum stelligerum, on the viability, proliferation, cell death and b-catenin, NFkB, STAT3/pSTAT3 and interleukins roles...
April 12, 2018: Anti-cancer Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/29644808/prognostic-evaluation-of-neurological-assessment-of-the-neuro-oncology-scale-in-glioblastoma-patients
#17
Jiwook Lee, Sung Hyun Park, Young Zoon Kim
BACKGROUND: The aims of this study were to investigate the role of the Neurological Assessment of Neuro-Oncology (NANO) scale in predicting the prognosis of patients with glioblastoma, and compare these results to predicted data of the Karnofsky Performance Scale (KPS), and Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance status. Additionally, we examined other prognostic factors in glioblastoma patients. METHODS: The medical records of 76 patients with a new diagnosis of histologically ascertained glioblastoma in the period from January 2002 to December 2015 at the authors' institution were retrospectively reviewed...
April 2, 2018: Brain Tumor Research and Treatment
https://www.readbyqxmd.com/read/29642503/migration-invasion-of-malignant-gliomas-and-implications-for-therapeutic-treatment
#18
REVIEW
Ching-Ann Liu, Chia-Yu Chang, Kuo-Wei Hsueh, Hong-Lin Su, Tzyy-Wen Chiou, Shinn-Zong Lin, Horng-Jyh Harn
Malignant tumors of the central nervous system (CNS) are among cancers with the poorest prognosis, indicated by their association with tumors of high-level morbidity and mortality. Gliomas, the most common primary CNS tumors that arise from neuroglial stem or progenitor cells, have estimated annual incidence of 6.6 per 100,000 individuals in the USA, and 3.5 per 100,000 individuals in Taiwan. Tumor invasion and metastasis are the major contributors to the deaths in cancer patients. Therapeutic goals including cancer stem cells (CSC), phenotypic shifts, EZH2/AXL/TGF-β axis activation, miRNAs and exosomes are relevant to GBM metastasis to develop novel targeted therapeutics for GBM and other brain cancers...
April 8, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29629823/durable-response-to-bevacizumab-in-adults-with-recurrent-pilocytic-astrocytoma
#19
Andrea Wasilewski, Nimish Mohile
BACKGROUND: Adult pilocytic astrocytomas are rare and highly vascular tumors. AIM: We hypothesized that they may be uniquely responsive to bevacizumab (BEV). PATIENTS: We present four adult patients with pathologically diagnosed WHO grade I pilocytic astrocytoma who had robust and durable responses to BEV at time of recurrence. Three patients developed radiographic changes on MRI, consistent with progressive disease based on response assessment in neuro-oncology criteria...
April 9, 2018: CNS Oncology
https://www.readbyqxmd.com/read/29627863/the-codesign-of-an-interdisciplinary-team-based-intervention-regarding-initiating-palliative-care-in-pediatric-oncology
#20
Douglas L Hill, Jennifer K Walter, Jessica A Casas, Concetta DiDomenico, Julia E Szymczak, Chris Feudtner
PURPOSE: Children with advanced cancer are often not referred to palliative or hospice care before they die or are only referred close to the child's death. The goals of the current project were to learn about pediatric oncology team members' perspectives on palliative care, to collaborate with team members to modify and tailor three separate interdisciplinary team-based interventions regarding initiating palliative care, and to assess the feasibility of this collaborative approach. METHODS: We used a modified version of experience-based codesign (EBCD) involving members of the pediatric palliative care team and three interdisciplinary pediatric oncology teams (Bone Marrow Transplant, Neuro-Oncology, and Solid Tumor) to review and tailor materials for three team-based interventions...
April 7, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
keyword
keyword
1438
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"